Stay updated on ANIMATE: Nivolumab in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the ANIMATE: Nivolumab in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ANIMATE: Nivolumab in Hodgkin Lymphoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' on the webpage has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change likely pertains to medical and healthcare-related publications and documentation.
    Difference
    24%
    Check dated 2024-05-22T07:55:22.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change likely indicates an update or revision in the estimated study completion date for the Phase II study of Nivolumab Monotherapy in patients with Relapsed/Refractory Hodgkin Lymphoma.
    Difference
    0.1%
    Check dated 2024-05-14T01:37:52.000Z thumbnail image
  7. Check
    13 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 2023 to 2024, indicating an update in the estimated study completion date for the Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma at The Christie Hospital in Manchester, United Kingdom.
    Difference
    1%
    Check dated 2024-05-11T17:36:34.000Z thumbnail image
  8. Check
    24 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:47:37.000Z thumbnail image

Stay in the know with updates to ANIMATE: Nivolumab in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ANIMATE: Nivolumab in Hodgkin Lymphoma Clinical Trial page.